Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio clinico dell'endoprotesi Treovance per pazienti con aneurismi dell'aorta addominale

10 novembre 2026 aggiornato da: Bolton Medical

Uno studio clinico di fase II sulla sicurezza e le prestazioni dell'endoprotesi Treovance con sistema di rilascio Navitel per pazienti con aneurismi dell'aorta addominale infrarenale

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

  • Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
  • Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

158

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • University of Alabama-Birmingham
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Arizona Heart Institute
    • Connecticut
      • Danbury, Connecticut, Stati Uniti, 06810
        • Danbury Hospital
    • Florida
      • Boca Raton, Florida, Stati Uniti, 33486
        • Lynn Heart and Vascular Institute
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Northside Hospital Heart & Vascular Institute
    • Illinois
      • Champaign, Illinois, Stati Uniti, 61820
        • Presence Medical Center -- Christie Clinic
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago
      • Rockford, Illinois, Stati Uniti, 61103
        • Affiliated Surgeons of Rockford Memorial Hospital
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts University Medical Center
      • Worcester, Massachusetts, Stati Uniti, 01655
        • University of Massachusetts
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic
    • New York
      • Albany, New York, Stati Uniti, 12205
        • Community Care (previously Albany Medical Center)
      • Buffalo, New York, Stati Uniti, 14203
        • Buffalo General Medical Center
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Medical Center
      • Rochester, New York, Stati Uniti, 14623
        • University of Rochester -- Strong Memorial Hospital
      • Stony Brook, New York, Stati Uniti, 11794-8191
        • Stony Brook Medical Center
    • North Carolina
      • Asheville, North Carolina, Stati Uniti, 28801
        • Mission Hospital
      • Greenville, North Carolina, Stati Uniti, 27834
        • East Carolina University / Pitt County Memorial Hospital
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Stati Uniti, 43210
        • The Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19140
        • Temple University School of Medicine
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • University of Pittsburgh Medical Center
      • York, Pennsylvania, Stati Uniti, 17403
        • York Hospital
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02905
        • Rhode Island Hospital
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57117
        • Sanford University of South Dakota Medical Center
      • Sioux Falls, South Dakota, Stati Uniti, 51108
        • North Central Heart (Avera Heart Hospital)
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23507
        • Sentara Vascular Specialists

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Subject must be between the ages of 18 and 85
  2. Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure
  3. Subject must have an infrarenal AAA that i. is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months
  4. Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm
  5. Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices
  6. Subject must have lowest renal artery at least 9 cm from the aortic bifurcation
  7. Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of >13 mm - 20 mm and a length of at least 15 mm
  8. Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU
  9. Subject must have a total treatment length of at least 13 cm
  10. Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same
  11. Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years
  12. Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs
  13. Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit.
  14. Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form

Exclusion Criteria:

  1. Subject is pregnant or lactating
  2. Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
  3. Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery
  4. Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging
  5. Subject has a lesion that cannot be crossed by a guide wire
  6. Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks
  7. Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction < 20%, or recent diagnosis of Congestive Heart Failure (CHF)
  8. Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date
  9. Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)
  10. Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis)
  11. Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta
  12. Subject has connective tissue disease (e.g., Marfan's syndrome)
  13. Subject has a mycotic aneurysm
  14. Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck
  15. Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone
  16. Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency
  17. Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair
  18. Subject is in acute or chronic renal failure (creatinine > 2.5 mg/dL) unless subject is stable on dialysis
  19. Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.)
  20. Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure
  21. Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion.
  22. Subject has had a prior AAA repair (endovascular or surgical)
  23. Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester
  24. Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treovance

Subjects who receive the Treovance stent-graft

Eligible subjects will be implanted with the Treovance Stent-Graft

Altri nomi:
  • Endoprotesi addominale Treovance con sistema di rilascio Navitel

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Primary Efficacy
Lasso di tempo: 12 months

Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.)

12 months
Primary Safety
Lasso di tempo: 30 days

The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.)

30 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Secondary Efficancy Endpoint -- Aneurysm-Related Mortality
Lasso di tempo: Annually to 5-years; annually to 10-years (stent-fracture subjects only)

Aneurysm-related mortality at 12 month and annually to 5 years; annually to 10 years for subjects with Core Lab-confirmed fracture(s)

Annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Technical Success
Lasso di tempo: 30 days

Technical success at 30 days confirmed by an imaging modality (e.g. CT)

30 days
Secondary Efficacy Endpoint -- Clinical Utility Measures
Lasso di tempo: Perioperative/Periprocedural

Clinical utility measures (procedure time, time in the intensive care unit, length of hospital stay)

Perioperative/Periprocedural
Secondary Efficacy Endpoint -- Secondary interventions
Lasso di tempo: 30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)

The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant

30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Device-Related Events
Lasso di tempo: 30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)

This endpoint includes the rate of events associated with the device.

30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Safety Endpoint -- Individual Rate for Events included in the composite MAE
Lasso di tempo: 30 days, 6 months, annually to 5 years

Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually to 5 years

30 days, 6 months, annually to 5 years
Secondary Safety Endpoint -- Procedure-Related Complications
Lasso di tempo: 30 days, 6 months, annually to 5 years

Procedure-related complications at 30 days, 6 months, 12 months, and annually to 5 years.

30 days, 6 months, annually to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Matthew Eagleton, MD, Cleveland Clinic Foundaton

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 novembre 2013

Completamento primario (Effettivo)

20 marzo 2017

Completamento dello studio (Effettivo)

22 gennaio 2026

Date di iscrizione allo studio

Primo inviato

6 novembre 2013

Primo inviato che soddisfa i criteri di controllo qualità

9 dicembre 2013

Primo Inserito (Stimato)

12 dicembre 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IP-0008-12

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .